Clinical utility of endoscopic ultrasound-guided tissue acquisition for comprehensive genomic profiling of patients with biliary tract cancer, especially with intrahepatic cholangiocarcinoma
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Endoscopic ultrasound-guided tissue acquisition (EUS-TA) is a standard diagnostic method for biliary tract cancer (BTC), and samples obtained in this manner may be used for comprehensive genomic profiling (CGP). This study evaluated the utility of EUS-TA for CGP in a clinical setting and determined the factors associated with the adequacy of CGP in patients with BTC. Methods: CGP was attempted for 105 samples from 94 patients with BTC at the Aichi Cancer Center, Japan, from October 2019 to April 2022. Results: Overall, 77.1% (81/105) of the samples were adequate for CGP. For 22-G or 19-G fine-needle biopsy (FNB), the sample adequacy was 85.7% (36/42), which was similar to that of surgical specimens (94%, p=0.45). Univariate analysis revealed that 22-G or larger FNB needle usage (86%, p=0.003), the target primary lesions (88%, p=0.015), a target size ≥30 mm (100%, p=0.0013), and number of punctures (90%, p=0.016) were significantly positively associated with CGP sample adequacy. Conclusions: EUS-TA is useful for CGP tissue sampling in patients with BTC. In particular, the use of 22-G or larger FNB needles may allow for specimen adequacy comparable to that of surgical specimens.
Abstract
Background/Aims: Endoscopic ultrasound-guided tissue acquisition (EUS-TA) is a standard diagnostic method for biliary tract cancer (BTC), and samples obtained in this manner may be used for comprehensive genomic profiling (CGP). This study evaluated the utility of EUS-TA for CGP in a clinical setting and determined the factors associated with the adequacy of CGP in patients with BTC. Methods: CGP was attempted for 105 samples from 94 patients with BTC at the Aichi Cancer Center, Japan, from October 2019 to April 2022. Results: Overall, 77.1% (81/105) of the samples were adequate for CGP. For 22-G or 19-G fine-needle biopsy (FNB), the sample adequacy was 85.7% (36/42), which was similar to that of surgical specimens (94%, p=0.45). Univariate analysis revealed that 22-G or larger FNB needle usage (86%, p=0.003), the target primary lesions (88%, p=0.015), a target size ≥30 mm (100%, p=0.0013), and number of punctures (90%, p=0.016) were significantly positively associated with CGP sample adequacy. Conclusions: EUS-TA is useful for CGP tissue sampling in patients with BTC. In particular, the use of 22-G or larger FNB needles may allow for specimen adequacy comparable to that of surgical specimens.
참고문헌 (21)
- "Cancer Statistics in Japan 2022" (2022)[URL]
- Miyakawa S, "Biliary tract cancer treatment : 5, 584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan", J Hepatobiliary Pancreat Surg, 16, pp.1~7 (2009)
- Valle J, "Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer", N Engl J Med, 362, pp.1273~1281 (2010)
- Ioka T, "Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer(KHBO1401-MITSUBA)", J Hepatobiliary Pancreat Sci, 30, pp.102~110 (2023)
- Oh DY, "A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin(GemCis)in patients(pts)with advanced biliary tract cancer(BTC) : TOPAZ-1", J Clin Oncol, 40(4_suppl), pp.378~ (2022)
- Lamarca A, "Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer(ABC-06) : a phase 3, open-label, randomised, controlled trial", Lancet Oncol, 22, pp.690~701 (2021)
- Yoo C, "Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin(NIFTY) : a multicentre, open-label, randomised, phase 2b study", Lancet Oncol, 22, pp.1560~1572 (2021)
- Nakamura H, "Genomic spectra of biliary tract cancer", Nat Genet, 47, pp.1003~1010 (2015)
- Sadeghi A, "Diagnostic yield of EUS-guided FNA for malignant biliary stricture : a systematic review and meta-analysis", Gastrointest Endosc, 83, pp.290~298 (2016)
- Cotton PB, "A lexicon for endoscopic adverse events : report of an ASGE workshop", Gastrointest Endosc, 71, pp.446~454 (2010)
- Navaneethan U, "Comparative effectiveness of biliary brush cytology and intraductal biopsy for detection of malignant biliary strictures : a systematic review and meta-analysis", Gastrointest Endosc, 81, pp.168~176 (2015)
- Rader AE, "Fine-needle aspiration biopsy diagnosis of gastrointestinal stromal tumors using morphology, immunocytochemistry, and mutational analysis of c-kit", Cancer, 93, pp.269~275 (2001)
- Kuwatani M, "Evolution and a promising role of EUS-FNA in gene and future analyses", Endosc Ultrasound, 9, pp.151~153 (2020)
- Hirata K, "A novel approach for the genetic analysis of biliary tract cancer specimens obtained through endoscopic ultrasound-guided fine needle aspiration using targeted amplicon sequencing", Clin Transl Gastroenterol, 10, pp.e00022~ (2019)
- Ikeda G, "Fine-needle biopsy with 19G needle is effective in combination with endoscopic ultrasound-guided tissue acquisition for genomic profiling of unresectable pancreatic cancer", Dig Endosc, 35, pp.124~133 (2023)
- Takahashi K, "Comparison of histological sample volumes among various endoscopic ultrasound-guided biopsy needles", J Clin Med, 10, pp.3560~ (2021)
- Boscoe AN, "Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma : a systematic literature review", J Gastrointest Oncol, 10, pp.751~765 (2019)
- Maruki Y, "Molecular detection and clinicopathological characteristics of advanced", recurrent biliary tract carcinomas harboring the FGFR2 rearrangements : a prospective observational study(PRELUDE Study), 2021, pp.56, 250~260
- Roa I, "Overexpression of the HER2", neu gene : a new therapeutic possibility for patients with advanced gallbladder cancer, 2014, pp.7, 42~48
- Israel MA, "Comparative genomic analysis of intrahepatic cholangiocarcinoma : biopsy type, ancestry, and testing patterns", Oncologist, 26, pp.787~796 (2021)
- Berchuck JE, "The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer", Ann Oncol, 33, pp.1269~1283 (2022)